InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,487.03
(
0.25%
)
US TECH 100
19,526.80
(
0.61%
)
Dow Jones
38,834.86
(
0.15%
)
Brent Oil
84.66
(
-0.05%
)
Bitcoin
65,693.09
(
1.12%
)
Post# of 252255
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

ciotera

Send PM Follow Ignore
Followers 8
Posts 511
Boards Moderated 0
Alias Born 08/03/2005

ciotera

Re: DewDiligence post# 150580

Monday, 10/15/2012 2:14:30 PM

Monday, October 15, 2012 2:14:30 PM

Post# of 252255

ABT’s HCV results ...




Agreed, but it's starting to look like efficacy is rapidly becoming a cost of entry in this space. If the other all-oral regimens (GILD, BMY) clear the 80-90% SVR hurdle but offer a much more tolerable (no ritonavir) and convenient (QD) option, ABT's regimen will not look very competitive.
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up